Skip to main content
COURAGE-ALS: a randomized, double-blind phase 3 study designed to improve participant experience and increase the probability of success
Relationship between quantitative strength and functional outcomes in the phase 2 FORTITUDE-ALS trial
Fast Skeletal Muscle Troponin Activator CK-4015089 Improves Muscle Function in a FSHD Mouse Model with Muscle Weakness
Feasibility Assessment of Using the MiToS Staging System for Conducting Economic Evaluation in Amyotrophic Lateral Sclerosis
Time From Amyotrophic Lateral Sclerosis Symptom Onset to Key Disease Milestones: Analysis of Data From a Multinational Cross-Sectional Survey
Site and Participant Perspectives on Participating in an ALS Trial Designed to Reduce Burden: COURAGE-ALS
COURAGE-ALS: Results of the Phase 3 Clinical Trial of Reldesemtiv in ALS
Investigating Geographical Differences in Time from ALS Symptom Onset to Key Disease Milestones: Data from a Real-World Survey
Plasma Neurofilament Analysis in VITALITY-ALS: Analysis at Baseline, Longitudinal, and by Rate of Disease Progression
Hospitalizations in COURAGE-ALS and their Relationship to ALS